7 results about "Human Immunoglobulin G" patented technology

The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.

The invention belongs to the field of biological medicines and medicinal preparations, and relates to a kynurenase-Fc fusion protein, a nano medicinal preparation thereof, a preparation method and application. The kynureninase-Fc fusion protein is formed by connecting kynureninase (KYNase) and an Fc structural domain of human immune globulin G. The invention further discloses a preparation method of the kynureninase-Fc fusion protein. Compared with PEG modified kynureninase, the kynureninase-Fc fusion protein has the advantages that the half-life period of KYNase in whole blood can be remarkably prolonged while the original KYNase activity is maintained, the concentration of a medicine at a tumor site is increased, and the anti-tumor effect of KYNase is improved. The nano-drug preparation based on the kynureninase-Fc fusion protein is prepared from the kynureninase-Fc fusion protein and a photosensitizer. According to the nano-drug preparation, the drug photosensitizer is entrapped in a non-covalent bond combination manner, so that the enrichment of the photosensitizer at a tumor site is improved, and the half-life period of the photosensitizer in whole blood is not changed. The kynureninase-Fc fusion protein provided by the invention can be used for anti-tumor immunotherapy, and the immunotherapy effect of tumor photodynamic therapy combined with kynureninase is enhanced.

The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).

This disclosure anti-human IgG antibodies and antigen-binding portions thereof derived from rabbits and methods of using these antibodies and portions.

The present invention relates to a stable liquid formulation of a fusion protein having an Fc domain of human immunoglobulin G (IgG) (in particular, a protein in which a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor and an Fc domain of human immunoglobulin G (IgG) are fused (e.g. Aflibercept)). The present invention also relates to a composition for stabilizing a protein in which a soluble extracellular domain of a VEGF receptor and an Fc domain of IgG are fused, and a method for stabilizing a protein in which a soluble extracellular domain of a VEGF receptor and an Fc domain of IgG are fused. The present invention can promote stabilization of physiological activity through a stable liquid formulation suitable for intravitreal injection of anti-VEGF-Fc fusion proteins including Aflibercept, and improve the therapeutic effect on various ophthalmic diseases caused by abnormal angiogenesis (e.g., retinal vein occlusion, diabetic macular edema, choroidal neovascularization, and wet age-related macular degeneration, etc.).

The present invention provides a radioactive protein-conjugated drug and its application, belonging to the field of biopharmaceuticals. The present invention provides a novel radioactive protein-conjugated drug, comprising at least one receptor-binding fragment fused to an Fc domain derived from human immunoglobulin G (IgG). Mutation modifications include L234, L235, and H435 of the Fc domain, and may also include P329 and / or D265. The preferred mutation combination is L234A, L235A, and H435Q. After chelating a radionuclide, the novel fusion protein provided by the present invention can be taken up at low doses in tissues such as the blood, kidneys, and liver, and rapidly cleared. It can also be taken up at high doses and for extended periods in tumor tissues, significantly improving the safety and efficacy of radiopharmaceutical therapy.

This invention provides a monoclonal antibody that is universally specific to human IgG but does not bind to monkey IgG. [Solution] An anti-human IgG antibody obtained from rabbits, its antigen-binding portion, and a method for using the antibody and portion are provided.